EQL Pharma Valuation

Q: What is the Fair Price of EQL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

EQL (SEK69.4) is trading below our estimate of [[fair value]] (SEK153.58)

Is EQL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EQL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: EQL (SEK69.4) is trading below our estimate of fair value (SEK153.58)

Significantly Below Fair Value: EQL is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EQL?

Key metric: As EQL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EQL. This is calculated by dividing EQL's market cap by their current earnings.
What is EQL's PE Ratio?
PE Ratio	64.7x
Earnings	SEK 31.18m
Market Cap	SEK 2.02b

EQL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.8x
Enterprise Value/EBITDA	39.9x
PEG Ratio	1.2x

Price to Earnings Ratio vs Peers

How does EQL's PE Ratio compare to its peers?

The above table shows the PE ratio for EQL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	18.6x
HUM Humana	15.2x	44.7%	SEK 1.9b
DEDI Dedicare	8.6x	n/a	SEK 569.0m
AMBEA Ambea	13.1x	11.5%	SEK 7.9b
STIL Stille	37.5x	35.0%	SEK 1.9b
EQL EQL Pharma	64.7x	53.3%	SEK 2.0b

Price-To-Earnings vs Peers: EQL is expensive based on its Price-To-Earnings Ratio (64.7x) compared to the peer average (18.6x).

Price to Earnings Ratio vs Industry

How does EQL's PE Ratio compare vs other companies in the European Healthcare Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: EQL is expensive based on its Price-To-Earnings Ratio (64.7x) compared to the European Healthcare industry average (18.8x).

Price to Earnings Ratio vs Fair Ratio

What is EQL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EQL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	64.7x
Fair PE Ratio	42x

Price-To-Earnings vs Fair Ratio: EQL is expensive based on its Price-To-Earnings Ratio (64.7x) compared to the estimated Fair Price-To-Earnings Ratio (42x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Dignitana

SEK 93.4m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.16

9.4%

-44.5%

Iconovo

SEK 78.0m

Develops and licenses inhalation medications in Sweden.

ICO

SEK 4.90

-4.3%

-44.3%

Arcoma

SEK 141.7m

Develops, produces, and provides radiology solutions worldwide.

ARCOMA

SEK 10.75

2.4%

52.5%